Floatz logo

sym015

MET Gene Mutation

Symphogen A/SPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MET Gene Mutation cohort.

Asset / SponsorPhaseRating
Crizotinib
Hunan Province Tumor Hospital
Phase 2CCC
VOLITINIB
Hunan Province Tumor Hospital
Phase 2CCC
ALECTINIB
Hunan Province Tumor Hospital
Phase 2CCC
Osimertinib
Hunan Province Tumor Hospital
Phase 2CCC
Capmatinib
Asan Medical Center
Phase 2CCC
egf816
Asan Medical Center
Phase 2CC

Same molecule, other indications

sym015 is also rated in:

MET Gene AmplificationDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →